An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer.
Christopher M Carosino, Devra J Olson, Rebecca C Mazahreh...
https://pubmed.ncbi.nlm.nih.gov/42008114/Actively Recruiting
Led by Pfizer · Updated on 2026-10-13
294
Participants Needed
68
Research Sites
156 weeks
Total Duration
Researchers are evaluating how a new medicine called PF-08052667 works alone or combined with Bacillus Calmette Guerin BCG andor sasanlimab in adults with a type of bladder cancer that has not spread into the muscle layer but is more likely to come back or grow. This study includes people whose cancer has returned or persisted despite standard treatments like BCG, as well as those who cannot receive or do not have access to standard treatments. The study is a phase 1 trial with three parts to test different dosing and combinations of these medicines. Participants receive PF-08052667 as an intravesical infusion directly into the bladder on days 1, 8, and 15 of a 21-day cycle. In Part 2 and Part 3, PF-08052667 is combined with BCG andor sasanlimab, with sasanlimab given as a subcutaneous injection under the skin. The study has three parts Part 1 tests increasing doses of PF-08052667 alone Part 2 tests combinations of PF-08052667 with BCG andor sasanlimab and Part 3 further explores optimal doses and combinations, including participants who have never had standard treatments. Participants will continue treatment until they choose to stop, are withdrawn for reasons such as side effects, or for up to about two years. Long-term follow-up will continue after treatment ends until loss to follow-up, death, or study completion. Researchers will monitor safety, side effects, lab results, and tumor responses, including recurrence-free and event-free survival. Participation duration varies based on individual circumstances and study progress.
CONDITIONS
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
P
Pfizer CT.gov Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pfizer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PF‑08052667 regimen | Current bladder‑preserving care |
|---|---|---|
| What it is | A sequential dose‑escalation and expansion study of intravesical PF‑08052667 (with PF‑02921367 bladder pre‑wash), alone or combined with sasanlimab and/or BCG | Bladder‑preserving strategies including intravesical chemotherapy, immune checkpoint inhibitors, and other local therapies used in BCG‑unresponsive NMIBC |
| Primary use | To evaluate safety, tolerability, and preliminary efficacy across dose levels in BCG‑unresponsive NMIBC | To control disease recurrence while avoiding radical cystectomy in BCG‑unresponsive cases |
| Evidence status | Under investigation; safety and efficacy not yet established | Used in practice with variable efficacy; checkpoint inhibitors and intravesical agents show modest control |
| Important risks | Not yet characterized; safety profile still being defined | Known risks include immune‑related adverse events with checkpoint inhibitors and local side effects from intravesical therapy |
| Important limitations | Single‑arm sequential design without comparator; long‑term benefit unknown | Limited long‑term disease control; radical cystectomy still often required due to recurrence risk |
| Patient impact | Not yet available | Can delay cystectomy and preserve bladder function, but recurrence remains common |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to about 2 years
Participants receive PF-08052667 through bladder infusion, alone or with BCG and/or sasanlimab injections, according to the study part and dosing schedule.
Visits on Days 1, 8, and 15 of a 21-day cycle
Duration - Up to approximately 2 years after treatment
Participants are monitored for safety, side effects, and cancer recurrence after treatment ends until loss to follow-up, death, or study completion.
Regular follow-up visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Christopher M Carosino, Devra J Olson, Rebecca C Mazahreh...
https://pubmed.ncbi.nlm.nih.gov/42008114/Pfizer
Lead Sponsor